John F. Chappell

This profile gathers the share dealings of John F. Chappell in Salix Pharmaceuticals Ltd. Over a trading history stretching from 19 May 2006 to 1 April 2015, the count stands at 81 filings.

No open-market purchase appears, only 20 sales worth €5.4M. The rest of the record consists of 10 share grants and 5 option exercises.

The newest entry dates from 3 April 2015: a transaction of €47.2M, in Salix Pharmaceuticals Ltd. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.